EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome

Kristyna Sloupenska iD, Barbora Koubkova, Pavel Horak iD, Beata Hutyrova, Mojmir Racansky, Jan Mares, Martina Miklusova, Jan Schovanek, Jana Zapletalova, Milan Raska iD, Michal Krupka iD

Life · 15.02.2023 · 13 (2) · 527

DOI: 10.3390/life13020527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 15.02.2023. Verfasst von Kristyna Sloupenska und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Czech Republic, Palacky University Olomouc, Ministry of Education, Youth and Sport of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most patients suffering from Lyme disease are effectively treated with antibiotics. In some patients, however, problems persist for a long time despite appropriate therapy. The term post-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientific literature. The pathogenesis is still not precisely known, but the involvement of immunopathological mechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositis-specific (MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory proven history of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting the criteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoing differential diagnosis of neurological disorders without clinical and/or laboratory-proven history of Lyme disease. The presence of autoantibodies was determined by immunoblot methods and positive samples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence of myositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5% of control subjects exhibiting no evidence of Lyme disease history. The difference was statistically significant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positive subjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raised MSA/MAA autoantibodies formation in the group of PTLDS patients raising the question about their involvement in the pathogenesis of this syndrome.

Schlagwörter

Stichwörter der Autor:innen

Lyme diseaseautoantibodiesmyositispost-treatment Lyme disease syndrome

Autor:innen und Institutionen

  • Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic.
  • Department of Allergology and Clinical Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic.
  • Third Department of Internal Medicine-Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic.
  • Department of Neurology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic.
  • Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic.
  • Department of Immunology, University Hospital Olomouc, Zdravotniku 248/7, 779 00 Olomouc, Czech Republic.

ORCID-Profile: Kristyna Sloupenska, Pavel Horak, Milan Raska, Michal Krupka

Förderung

  • Ministry of Health of the Czech Republic
  • Palacky University Olomouc
  • Ministry of Education, Youth and Sport of the Czech Republic
  • Ministry of Education, Youth, and Sport of the Czech Republic

Zitieren

APA

Sloupenska, K., Koubkova, B., Horak, P., Hutyrova, B., Racansky, M., Mares, J., Miklusova, M., Schovanek, J., Zapletalova, J., Raska, M., & Krupka, M. (2023). Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome. Life, 13(2), 527. https://doi.org/10.3390/life13020527

Vancouver

Sloupenska K, Koubkova B, Horak P, Hutyrova B, Racansky M, Mares J, et al. Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome. Life. 2023;13(2):527. doi:10.3390/life13020527

BibTeX
@article{Sloupenska2023,
  author = {Sloupenska, Kristyna and Koubkova, Barbora and Horak, Pavel and Hutyrova, Beata and Racansky, Mojmir and Mares, Jan and Miklusova, Martina and Schovanek, Jan and Zapletalova, Jana and Raska, Milan and Krupka, Michal},
  title = {Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {527},
  doi = {10.3390/life13020527}
}
Kostenlos starten →